Stuart Milstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10983955/publications.pdf

Version: 2024-02-01

236925 434195 9,384 32 25 31 citations h-index g-index papers 33 33 33 12054 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Towards a proteome-scale map of the human protein–protein interaction network. Nature, 2005, 437, 1173-1178.	27.8	2,676
2	A Map of the Interactome Network of the Metazoan <i>C. elegans</i> . Science, 2004, 303, 540-543.	12.6	1,587
3	Multivalent <i>N</i> -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. Journal of the American Chemical Society, 2014, 136, 16958-16961.	13.7	825
4	Therapeutic siRNA silencing in inflammatory monocytes in mice. Nature Biotechnology, 2011, 29, 1005-1010.	17.5	697
5	A Conserved Checkpoint Pathway Mediates DNA Damage–Induced Apoptosis and Cell Cycle Arrest in C. elegans. Molecular Cell, 2000, 5, 435-443.	9.7	476
6	Edgetic perturbation models of human inherited disorders. Molecular Systems Biology, 2009, 5, 321.	7.2	326
7	Empirically controlled mapping of the Caenorhabditis elegans protein-protein interactome network. Nature Methods, 2009, 6, 47-54.	19.0	260
8	hORFeome v3.1: A resource of human open reading frames representing over 10,000 human genes. Genomics, 2007, 89, 307-315.	2.9	248
9	An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine, 2015, 21, 492-497.	30.7	247
10	Caenorhabditis elegans HUS-1 Is a DNA Damage Checkpoint Protein Required for Genome Stability and EGL-1-Mediated Apoptosis. Current Biology, 2002, 12, 1908-1918.	3.9	244
11	Advanced siRNA Designs Further Improve InÂVivo Performance of GalNAc-siRNA Conjugates. Molecular Therapy, 2018, 26, 708-717.	8.2	202
12	A Protein Domain-Based Interactome Network for C. elegans Early Embryogenesis. Cell, 2008, 134, 534-545.	28.9	196
13	siRNA Conjugates Carrying Sequentially Assembled Trivalent <i>N-</i> Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing <i>In Vivo</i> io Hepatocytes. ACS Chemical Biology, 2015, 10, 1181-1187.	3.4	173
14	Hepatocyteâ€Specific Delivery of siRNAs Conjugated to Novel Nonâ€nucleosidic Trivalent <i>N</i> â€Acetylgalactosamine Elicits Robust Gene Silencing in Vivo. ChemBioChem, 2015, 16, 903-908.	2.6	151
15	Systematic Interactome Mapping and Genetic Perturbation Analysis of a C. elegans TGF-Î ² Signaling Network. Molecular Cell, 2004, 13, 469-482.	9.7	136
16	Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Molecular Therapy - Nucleic Acids, 2012, 1, e4.	5.1	112
17	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunology, Immunotherapy, 2013, 62, 285-297.	4.2	111
18	C. elegans ORFeome Version 3.1: Increasing the Coverage of ORFeome Resources With Improved Gene Predictions. Genome Research, 2004, 14, 2064-2069.	5.5	107

#	Article	IF	CITATIONS
19	Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Molecular Therapy - Nucleic Acids, 2015, 4, e263.	5.1	107
20	Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 109-118.	3.0	89
21	Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nature Biotechnology, 2022, 40, 1500-1508.	17.5	79
22	Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. Gastroenterology, 2020, 158, 1762-1775.e9.	1.3	78
23	'Edgetic' perturbation of a C. elegans BCL2 ortholog. Nature Methods, 2009, 6, 843-849.	19.0	71
24	C. elegans GLA-3 is a novel component of the MAP kinase MPK-1 signaling pathway required for germ cell survival. Genes and Development, 2006, 20, 2279-2292.	5.9	53
25	From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization. Nucleic Acids Research, 2022, 50, 6656-6670.	14.5	28
26	Apparent transgenerational effects of host plant in the leaf beetle Ophraella notulata (Coleoptera:) Tj ETQq0 0 C	rgBT/Ove	erlack 10 Tf 5
27	From genome to proteome: developing expression clone resources for the human genome. Human Molecular Genetics, 2006, 15, R31-R43.	2.9	26
28	RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models. Journal of Clinical Investigation, 2020, 130, 2928-2942.	8.2	25
29	Large-scale RACE approach for proactive experimental definition of C. elegans ORFeome. Genome Research, 2009, 19, 2334-2342.	5.5	12
30	Improving Drug Discovery by Nucleic Acid Delivery in Engineered Human Microlivers. Cell Metabolism, 2019, 29, 727-735.e3.	16.2	10
31	Differential regulation of germ line apoptosis and germ cell differentiation by CPEB family members in C. elegans. PLoS ONE, 2017, 12, e0182270.	2.5	5
32	Methods to Identify and Characterize siRNAs Targeting Serpin A1 In Vitro and In Vivo Using RNA Interference. Methods in Molecular Biology, 2017, 1639, 115-126.	0.9	0